Skip to main content

Table 2 Behaviour after inclusion and clearance of Chlamydia trachomatis based on RNA and DNA testing, by anatomical site

From: Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae – a prospective cohort study

Characteristics Total
n (%)a
Urethra
n (%)a
Rectum
n (%)a
Endocervix
n (%)a
P
Patients 23 7 (30.4) 7 (30.4) 9 (39.1)  
Behaviour after inclusion
 Median no. of samples collected (range) 28 (25–28) 28 (26–28) 28 (26–28) 27 (25–28) 0.01
 Patients with missed samples 11 (47.8) 1 (14.3) 2 (28.6) 8 (88.9) 0.009
  Median no. of missed samples (IQR) 1 (1–3) 2 (2–2) 1.5 (1–2) 1 (1–3) 0.86
 Rectal/vaginal douching 4 (25.0)g - 3 (42.9) 1 (11.1) 0.26
 Sexual contact 12 (52.2) 3 (42.9) 4 (57.1) 5 (55.6) 1.00
 Condomless sex 5 (21.7) 1 (14.3) 2 (28.6) 2 (22.2) 1.00
RNA clearanceb
 Clearance during follow-up 23 (100.0) 7 (100.0) 7 (100.0) 9 (100.0)  
 Day of clearance definablec 21 (91.3) 7 (100.0) 6 (85.7) 8 (88.9) 1.00
 Median time to clearance, days (range) 7 (1–13) 5 (1–13) 6.5 (5–9) 8 (6–13) 0.20
Blipsd
 Samples at risk for blip 411 140 126 145  
 Number of blips 18 0 12 6  
 Number of patients 8 (34.8) 0 (0.0) 3 (42.9) 5 (55.6) 0.09
 Median time to first blip from being at risk, days (range) 1 (1–16) - 1 (1–2) 4.5 (1–16) 0.61
DNA clearanceb,e
 Clearance during follow-up 22 (100.0) 6 (100.0) 7 (100.0) 9 (100.0)  
 Day of clearance definablef 21 (95.5) 6 (100.0) 7 (100.0) 8 (88.9)  
 Median time to clearance, days (range) 6 (1–15) 6 (1–14) 5 (2–9) 7.5 (5–15) 0.08
Blipsf
 Samples at risk for blip 403 117 138 144  
 Number of blips 7 0 0 7  
 Number of patients 5 (22.7) 0 0 5 (55.6) 0.01
 Median time to first blip from being at risk, days (range) 3 (2–8) - - 3 (2–8)  
 Mean Ct-value (range) 38.6 (35.3–41.7) - - 38.6 (35.3–41.7)  
  1. RNA ribonucleic acid, DNA deoxyribonucleic acid; IQR inter-quartile range; Ct cycle threshold
  2. aUnless otherwise indicated
  3. bBased on a definition of 3 consecutive negative tests following a positive test
  4. cFor 2 patients the exact day of clearance could not be defined due to missing samples in the period of clearance
  5. dBlip was defined as a positive test following clearance. Samples from all 23 patients were included; for those without an exact day of clearance due to missing samples, all samples after the first three consecutive negative results were considered at risk for blips
  6. eOne patient was excluded from this analysis because the sample at inclusion was negative for Chlamydia trachomatis DNA
  7. fFor 1 patient the exact day of clearance could not be defined due to missing samples in the period of clearance
  8. gRectal/vaginal douching was only reported on by the 16 patients with rectal/endocervical infection